Aprea TherapeuticsAPRE
Market Cap: $18.2M
About: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Employees: 7
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
17% more funds holding
Funds holding: 23 [Q1] → 27 (+4) [Q2]
2.0% less ownership
Funds ownership: 44.16% [Q1] → 42.16% (-2.0%) [Q2]
15% less capital invested
Capital invested by funds: $10.9M [Q1] → $9.32M (-$1.63M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Wedbush Robert Driscoll 61% 1-year accuracy 41 / 67 met price target | 228%upside $11 | Outperform Reiterated | 13 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 497%upside $20 | Buy Reiterated | 12 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 497%upside $20 | Buy Reiterated | 24 Jun 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 497%upside $20 | Buy Reiterated | 17 Jun 2024 |
Financial journalist opinion
Based on 3 articles about APRE published over the past 30 days